ArticleScientific reports2025
Correlations of serum myostatin and irisin with sarcopenia and osteoporosis in rheumatoid arthritis patients: a cross-sectional study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Reduced serum Irisin levels in systemic sclerosis: a cross-sectional case-control study.Clinical rheumatology · 2026Article
- Two-Way Communication Between Skeletal Muscle and Myokines.Cell biochemistry and function · 2026Review
- Wenyang Yishen Tongluo prescription synergizes with bone marrow mesenchymal stem cells to alleviate rheumatoid arthritis via inhibiting IL-6.Journal of molecular histology · 2026Article
- Resistance exercise exerts anti-hypertensive effects and downregulates NTPDase/CD39 and ecto-5'-nucleotidase/CD73 expression in patients with chronic kidney disease undergoing hemodialysis.Purinergic signalling · 2026Article
- Prevalence and risk factors of CKD-associated osteoporosis in maintenance hemodialysis patients aged over 50 years: a cross-sectional study.Scientific reports · 2026Article
- Transcending aging: disease specificity, assessment challenges, and management strategies for rheumatoid arthritis-related sarcopenia.Frontiers in medicine · 2026Review
- Potential efficacy and preliminary mechanistic insights of the Jianpi Yishen Zhuanggu Tongluo formula for rheumatoid arthritis with sarcopenia-osteopenia: an integrated pilot study.Frontiers in pharmacology · 2026Article
- The Influence of Irisin on Selected Organs-The Liver, Kidneys, and Lungs: The Role of Physical Exercise.Cells · 2025Review
- The Dual Role of Myokines in Fatigue Associated with Inflammatory Joint Diseases.Journal of inflammation research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Myostatin and irisin, the key regulators of muscle metabolism, are myokines secreted by skeletal muscles that significantly influence osteoporosis (OP) and sarcopenia. This study investigated the associations of serum myostatin and irisin levels with sarcopenia and OP prevalence in 182 rheumatoid arthritis (RA) versus 142 healthy controls. RA patients exhibited significantly elevated serum myostatin (P = 0.001) and reduced irisin levels (P = 0.009), with markedly higher rates of myostatin/irisin dysregulation compared to controls (both P < 0.0001). Subgroup analyses revealed that RA patients with sarcopenia had higher myostatin (P = 0.002) and lower irisin (P = 0.003) than RA patients without sarcopenia. Similarly, RA patients with osteoporotic fractures (OPF) showed increased myostatin (P = 0.045) and decreased irisin (P = 0.029) compared to those without OPF. Myostatin levels correlated positively with anti-cyclic citrullinated peptide (anti-CCP) antibodies (P = 0.041) and inversely with body mass index (BMI) (P = 0.003), while irisin levels were negatively associated with C-reactive protein (P = 0.040) and positively linked to skeletal muscle mass index (P = 0.036). Multivariate analyses identified the Sharp score as an independent risk factor for OP (OR = 1.005, 95% CI 1.000-1.010; P = 0.04). For sarcopenia, both Sharp score (OR = 1.008, 95% CI 1.002-1.014; P = 0.013) and elevated myostatin levels (OR = 1.222, 95% CI 1.015-1.472; P = 0.034) were significant risk predictors, whereas higher irisin levels conferred protection (OR = 0.963, 95% CI 0.936-0.990; P = 0.007). Elevated serum myostatin and reduced irisin levels are associated with sarcopenia and OPF in RA patients. Sharp scores are identified as a risk factor for OP in RA patients. Additionally, Sharp scores and elevated myostatin levels serve as risk factors for sarcopenia, while irisin levels act as a protective factor against sarcopenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.